Quinton Announces Distribution Agreement in Japan.

Business Editors & Health/Medical Writers

BOTHELL, Wash.--(BUSINESS WIRE)--June 13, 2002

Quinton Cardiology Systems, Inc. (Nasdaq:QUIN), a global leader in advanced cardiology products, announced the establishment of a distribution agreement with Nihon Kohden Corporation of Tokyo, Japan.

Nihon Kohden is one of the leading manufacturers and distributors of diagnostic cardiology products in the world. Founded in 1951, Nihon Kohden developed the 8-channel electroencephalograph which was the first to be completely powered from the AC lines, an EKG system using a photographic process to view the waveforms and a kymograph chart recorder to record variations in blood pressure or muscle tension. Since then the company has produced many innovative products in cardiology, telemetry, pulse oximetry and bedside monitoring. Nihon Kohden will have distribution rights for Quinton cardiology products for three years, with contract renewal options. This agreement significantly strengthens Quinton's reach into the Japanese market, the third largest market for medical devices in the world.

"We are pleased to announce this agreement with Nihon Kohden," said Quinton President, John Hinson. "Their experience in the cardiology device business is outstanding and Quinton is fortunate to have secured such a strong partner as we move forward in this market."

As part of the agreement Quinton will customize products for the Japanese market. The first of these efforts is the conversion of the Q-Stress cardiac stress monitor to display Japanese language (Kanji) characters. "The localization of our Q-Stress monitor for the Japanese market is exciting for Quinton and Nihon Kohden. This project, along with Nihon Kohden's strong distribution and experience in cardiac stress monitoring, should quickly establish the system in Japan," stated Alex Castro, Director of International Sales for Quinton. The Q-Stress system is the current market leader in the U.S.

Quinton develops, manufactures, markets and services a family of diagnostic cardiology systems used in the diagnosis, treatment and rehabilitation of patients with cardiovascular disease. Quinton shares are quoted on the Nasdaq National Market under the trading symbol "QUIN".

This press release contains forward-looking statements relating to Quinton anticipated growth and future operating results that involve a number of risks and uncertainties. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results include, but are not limited to, reduced demand for our products, delays in our product development activities and commercial introduction of product enhancements and new products, changes in competitors' products or their pricing which may impair the market acceptance of our products or force us to lower our prices, disruptions in third party supplies of certain components we use in our products, the impact of acquisitions and divestitures, and costs associated with ongoing litigation against a former supplier. These and other risks are more fully described under the caption "Risk Factors" included in our Prospectus as filed with the Securities and Exchange Commission by Quinton Cardiology Systems, Inc. Quinton undertakes no duty or obligation to update the information provided herein.